Shandong Keyuan Pharmaceutical Co. Ltd. A (SHE:301281) — Market Cap & Net Worth
Market Cap & Net Worth: Shandong Keyuan Pharmaceutical Co. Ltd. A (301281)
Shandong Keyuan Pharmaceutical Co. Ltd. A (SHE:301281) has a market capitalization of $793.42 Million (CN¥5.42 Billion) as of June 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #10116 globally and #2716 in its home market, demonstrating a 11.22% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shandong Keyuan Pharmaceutical Co. Ltd. A's stock price CN¥50.07 by its total outstanding shares 108290000 (108.29 Million). Review 301281 total debt and obligations to assess the company's total debt and financial obligations.
Shandong Keyuan Pharmaceutical Co. Ltd. A Market Cap History: 2023 to 2026
Shandong Keyuan Pharmaceutical Co. Ltd. A's market capitalization history from 2023 to 2026. Data shows growth from $533.20 Million to $793.42 Million (21.26% CAGR).
Shandong Keyuan Pharmaceutical Co. Ltd. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shandong Keyuan Pharmaceutical Co. Ltd. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.02x
Shandong Keyuan Pharmaceutical Co. Ltd. A's market cap is 1.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
7.84x
Shandong Keyuan Pharmaceutical Co. Ltd. A's market cap is 7.84 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $533.20 Million | $447.58 Million | $77.04 Million | 1.19x | 6.92x |
| 2024 | $473.96 Million | $463.72 Million | $60.45 Million | 1.02x | 7.84x |
Competitor Companies of 301281 by Market Capitalization
Companies near Shandong Keyuan Pharmaceutical Co. Ltd. A in the global market cap rankings as of June 19, 2026.
Key companies related to Shandong Keyuan Pharmaceutical Co. Ltd. A by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #14 globally with a market cap of $936.50 Billion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #17 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Johnson & Johnson (NYSE:JNJ): Ranked #27 globally with a market cap of $550.26 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #41 globally with a market cap of $356.49 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #14 | Eli Lilly and Company | NYSE:LLY | $936.50 Billion | $1098.57 |
| #17 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #27 | Johnson & Johnson | NYSE:JNJ | $550.26 Billion | $228.39 |
| #41 | AbbVie Inc | NYSE:ABBV | $356.49 Billion | $216.49 |
Shandong Keyuan Pharmaceutical Co. Ltd. A Historical Marketcap From 2023 to 2026
Between 2023 and today, Shandong Keyuan Pharmaceutical Co. Ltd. A's market cap moved from $533.20 Million to $ 793.42 Million, with a yearly change of 21.26%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥793.42 Million | +70.89% |
| 2025 | CN¥464.29 Million | -2.04% |
| 2024 | CN¥473.96 Million | -11.11% |
| 2023 | CN¥533.20 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Shandong Keyuan Pharmaceutical Co. Ltd. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $793.42 Million USD |
| MoneyControl | $793.42 Million USD |
| MarketWatch | $793.42 Million USD |
| marketcap.company | $793.42 Million USD |
| Reuters | $793.42 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shandong Keyuan Pharmaceutical Co. Ltd. A
Shandong Keyuan Pharmaceutical Co., Ltd. is involved in the research and development, manufacture, and marketing of chemical raw materials and their preparations. It offers gliclazide; metformin hydrochloride; isosorbide mononitrate; isosorbide dinitrate; lansoprazole; mecobalamin; ropivacaine hydrochloride; isoflurane; fluoxetine hydrochloride; clemastine fumarate; chlorpheniramine maleate; esmo… Read more